Group One Trading
VYGR icon

Group One Trading’s Voyager Therapeutics VYGR Stock Holding History

Group One Trading’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$171K Buy
44,300
+32,500
+275% +$128K ﹤0.01% 4253
2025
Q4 		$46.4K Sell
11,800
-2,800
-19% -$12.4K ﹤0.01% 5662
2025
Q3 		$68.2K Buy
14,600
+12,800
+711% +$46.3K ﹤0.01% 5702
2025
Q2 		$5.6K Sell
1,800
-29,800
-94% -$96.1K ﹤0.01% 7036
2025
Q1 		$107K Sell
31,600
-5,900
-16% -$27.6K ﹤0.01% 4548
2024
Q4 		$213K Buy
37,500
+32,600
+665% +$210K ﹤0.01% 3895
2024
Q3 		$28.7K Buy
4,900
+1,600
+48% +$11.6K ﹤0.01% 5023
2024
Q2 		$26.1K Buy
3,300
+1,000
+43% +$8.38K ﹤0.01% 5035
2024
Q1 		$21.4K Buy
+2,300
New +$19.4K ﹤0.01% 5367
2023
Q4 		– Sell
-1,300
Closed -$10.1K – 8271
2023
Q3 		$10.1K Sell
1,300
-5,800
-82% -$53K ﹤0.01% 6332
2023
Q2 		$81.3K Sell
7,100
-111,300
-94% -$1.15M ﹤0.01% 4823
2023
Q1 		$913K Buy
118,400
+87,800
+287% +$698K ﹤0.01% 2217
2022
Q4 		$187K Sell
30,600
-316,300
-91% -$1.8M ﹤0.01% 3916
2022
Q3 		$2.05M Buy
346,900
+1,800
+0.5% +$11.5K ﹤0.01% 1900
2022
Q2 		$2.04M Buy
345,100
+325,100
+1,626% +$2.2M ﹤0.01% 2042
2022
Q1 		$152K Buy
20,000
+9,800
+96% +$43.7K ﹤0.01% 5083
2021
Q4 		$28K Sell
10,200
-7,800
-43% -$26.6K ﹤0.01% 6768
2021
Q3 		$47K Buy
18,000
+6,000
+50% +$19.5K ﹤0.01% 6592
2021
Q2 		$50K Buy
12,000
+5,100
+74% +$23.1K ﹤0.01% 6584
2021
Q1 		$33K Buy
6,900
+1,100
+19% +$7.5K ﹤0.01% 6491
2020
Q4 		$41K Buy
5,800
+1,600
+38% +$15.4K ﹤0.01% 5139
2020
Q3 		$45K Sell
4,200
-19,900
-83% -$234K ﹤0.01% 4704
2020
Q2 		$304K Buy
24,100
+20,600
+589% +$240K ﹤0.01% 3037
2020
Q1 		$32K Buy
3,500
+3,000
+600% +$34.4K ﹤0.01% 3995
2019
Q4 		$7K Sell
500
-7,200
-94% -$105K ﹤0.01% 4694
2019
Q3 		$133K Sell
7,700
-6,600
-46% -$139K ﹤0.01% 3366
2019
Q2 		$389K Buy
14,300
+14,200
+14,200% +$325K ﹤0.01% 2362
2019
Q1 		$2K Sell
100
-600
-86% -$7.82K ﹤0.01% 4608
2018
Q4 		$9K Buy
700
+500
+250% +$6.42K ﹤0.01% 4313
2018
Q3 		$4K Sell
200
-1,200
-86% -$23K ﹤0.01% 4918
2018
Q2 		$27K Sell
1,400
-200
-13% -$3.95K ﹤0.01% 4255
2018
Q1 		$30K Sell
1,600
-14,100
-90% -$305K ﹤0.01% 3913
2017
Q4 		$261K Sell
15,700
-7,100
-31% -$122K ﹤0.01% 2759
2017
Q3 		$469K Buy
+22,800
New +$257K ﹤0.01% 2125

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Group One Trading's VYGR Position: Q1 2026 in Review

Group One Trading reduced its Voyager Therapeutics (VYGR) stake by 71% in Q1 2026, selling an estimated $5.76K and leaving 610 shares worth $2.35K. The position accounts for ﹤0.01% of the portfolio, ranked #7003.

Group One Trading first reported a position in VYGR in Q2 2017 and has held it in 14 quarters since. The position peaked at $199K in Q3 2017. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Group One Trading held 610 shares of Voyager Therapeutics worth $2.35K as of Q1 2026.
  • Group One Trading sold 1,464 Voyager Therapeutics shares in Q1 2026, an estimated $5.76K.
  • Voyager Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7003 holding.
  • Group One Trading first reported a position in Voyager Therapeutics in Q2 2017 and has held it in 14 quarters since.
  • Group One Trading's Voyager Therapeutics position peaked at $199K in Q3 2017.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.